Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID-19: a randomized, double-blind, placebo-controlled trial
bovhyaluronidase azoximer improved exercise tolerance and reduced breathlessness in post-COVID-19 patients.
Faster lung recovery was noted in those with cardiovascular issues after 180 days.